What's New in Breast Cancer - Susan G. Komen®
Learn about new breast cancer treatment breakthroughs and recent developments in research that are fueling new ways to assess risk, prevent, detect and diagnose breast cancer.
Powerful new therapy doubles progression-free survival in …
Oct 31, 2024 · A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the...
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast ...
Feb 14, 2024 · A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a chemical change to stop tumor cells from dividing ...
Our top 5 research breakthroughs of 2023 | Breast Cancer Now
Dec 21, 2023 · Research is the key to stopping breast cancer in its tracks. And our scientists have been working hard throughout the year to better understand breast cancer. With this comes some amazing discoveries, from improving treatments to discovering new …
What’s New in Breast Cancer Research? - American Cancer Society
Breast cancer treatment. New kinds of treatments for breast cancer are always being studied. For example, in recent years, several new targeted drugs have been approved to treat breast cancer. But more and better treatment options are needed, especially for cancers like triple-negative breast cancer, where chemotherapy is the main option.
Advances in Breast Cancer Research - NCI - National Cancer …
This page highlights what's new and recent research in the detection and treatment of breast cancer. New methods to detect breast cancer, such as 3-D mammography, are described. Treatments tailored to breast cancer subtypes are discussed, including targeted therapies.
FDA Approves New Drug Combination for ER+, HER2- Breast Cancer
Oct 10, 2024 · The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets PIK3CA mutations, appears to be a vital addition to making the triplet therapy more effective.
What’s New in Breast Cancer Research? SABCS24 Looks at …
Dec 31, 2024 · Researchers also presented findings about safely reducing the effects of breast cancer surgery and treatment. Results from the INSEMA trial, which followed patients for six years, ... For now, studies are using it to follow patients and assess the efficacy of new treatments. Analysis from the postMONARCH trial, for instance, showed ctDNA to be ...
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer ...
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist ...
Current and future immunotherapy for breast cancer
Dec 25, 2024 · Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to expand the current treatment landscape for immune checkpoint inhibitors in ...